Xponance Inc. Buys 1,699 Shares of Hologic, Inc. (NASDAQ:HOLX)

Xponance Inc. boosted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 5.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 35,726 shares of the medical equipment provider’s stock after purchasing an additional 1,699 shares during the quarter. Xponance Inc.’s holdings in Hologic were worth $2,207,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Allworth Financial LP raised its stake in Hologic by 46.0% during the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock valued at $40,000 after purchasing an additional 216 shares during the period. EverSource Wealth Advisors LLC raised its stake in Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 260 shares during the period. Raiffeisen Bank International AG bought a new stake in Hologic during the 4th quarter valued at approximately $49,000. West Financial Advisors LLC bought a new stake in Hologic during the 1st quarter valued at approximately $50,000. Finally, Covestor Ltd raised its stake in Hologic by 49.3% during the 4th quarter. Covestor Ltd now owns 1,033 shares of the medical equipment provider’s stock valued at $75,000 after purchasing an additional 341 shares during the period. Institutional investors own 94.73% of the company’s stock.

Hologic Trading Down 1.7%

NASDAQ:HOLX opened at $64.62 on Tuesday. The firm has a market cap of $14.40 billion, a PE ratio of 27.27, a price-to-earnings-growth ratio of 2.41 and a beta of 0.55. The stock has a fifty day moving average price of $61.55 and a 200 day moving average price of $63.41. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $84.67. The company has a current ratio of 3.24, a quick ratio of 2.52 and a debt-to-equity ratio of 0.54.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. During the same period last year, the business posted $1.03 earnings per share. Hologic’s revenue was down 1.2% compared to the same quarter last year. Sell-side analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Activity at Hologic

In related news, Director Martin D. Madaus purchased 5,445 shares of the stock in a transaction that occurred on Wednesday, May 7th. The shares were purchased at an average price of $55.24 per share, with a total value of $300,781.80. Following the completion of the acquisition, the director directly owned 5,445 shares in the company, valued at $300,781.80. This represents a ? increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 1.88% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Citigroup raised Hologic from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $60.00 to $80.00 in a research note on Wednesday, July 9th. Wall Street Zen downgraded Hologic from a “buy” rating to a “hold” rating in a research note on Monday, May 5th. Stephens reduced their price objective on Hologic from $77.00 to $70.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 13th. Morgan Stanley reduced their price objective on Hologic from $77.00 to $65.00 and set an “equal weight” rating on the stock in a research note on Monday, May 5th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Hologic in a research note on Tuesday, May 27th. Eleven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $78.75.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.